AzTrials
AzTrials

Atrial Fibrillation (AF)NCT06832033

Concurrent Training in Patients Undergoing Atrial Fibrillation Ablation.

A study testing Exercise in people with Atrial Fibrillation (AF) and Physical Exercise, run by Marcos Echevarría at 1 site in Spain.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Atrial fibrillation (AF) is an irregular and often very fast heart rhythm, is considered the most common sustained cardiac arrhythmia in adults worldwide, and its incidence and prevalence are increasing. Currently, the estimated prevalence of AF in adults is 2-4%, and is projected to increase 2.3-fold. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Exercise
Could I receive a placebo?
No, everyone receives an active treatment
How many people
120 participants
Where
1 siteSpain
Study dates
9 Sep 2024to Sep 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients aged ≥18 years
  • Undergoing catheter ablation as medical treatment for AF at least one year prior to enrollment.

Who cannot join

  • Patients who do not sign the informed consent for participation in the study.
  • Severe atrial dilatation.
  • Structural heart disease.
  • Pathology that prevents the normal practice of intervention with physical exercise

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Marcos Echevarría Polo, PhD Student contact

+34 640554122

mechevarria@unizar.es

Nuria Garatachea Vallejo, PhD contact

+34 606777435

nugarata@unizar.es

Spain1 site, 1 recruiting
  • University of Zaragoza

    Zaragoza, Zaragoza, 50009

    Recruiting

Other trials in Spain

About this study

Official title: Effects of a Concurrent Physical Exercise Program in Patients Undergoing Atrial Fibrillation Ablation on Fibrillation Burden, Cardiac Morphology and Function, Physical Fitness, Physical Activity, Body Composition and Quality of Life.

Atrial fibrillation (AF) is an irregular and often very fast heart rhythm, is considered the most common sustained cardiac arrhythmia in adults worldwide, and its incidence and prevalence are increasing. Currently, the estimated prevalence of AF in adults is 2-4%, and is projected to increase 2.3-fold.

AF is associated with increased morbimortality and other comorbidities (hypertension diabetes etc.) which places a significant burden on the patient himself, social health and also on health and social care expenditure.

Read more

The European Society of Cardiology proposes an integrated ABC model (A: Anticoagulation, B: main symptom management, C: optimization of comorbidities and cardiovascular) and within this model, catheter ablation (B) is considered one of the main treatments to control AF symptoms; physical activity (C) is considered one of the modifiable health risk factors and is considered within a lifestyle intervention together with weight loss.

Catheter ablation of AF is currently the treatment of choice for paroxysmal AF. It uses small burns or frostbite to cause some scarring inside the heart to help interrupt the electrical signals that cause the irregular heartbeat. It is a safe procedure that has been shown to be more effective than treatment with antiarrhythmic drugs in reducing the arrhythmic burden and, therefore, the morbidity and mortality associated with the pathology.

Many studies have demonstrated the beneficial effects of moderate physical activity and physical exercise on cardiovascular health. However, there is still controversy as to whether physical activity is associated with an increased risk of AF in the general population; while some studies report a decreased risk of AF, others suggest an increase or that there is no evidence of an association between AF and physical activity.

Few studies have yet focused on the effects of physical activity in those subjects who have undergone catheter ablation. Studies that have evaluated physical activity with questionnaires associate it, when of moderate or high intensity, with lower recurrence of AF and lower incidence of serious events. It is true that the practice of regular and controlled physical exercise is a recognized part of the comprehensive care of patients with coronary heart disease (patients whose heart has difficulty receiving blood), and exercise is systematically identified as a central element of their rehabilitation. However, to date there is no similar approach for AF ablation patients.

Given the current situation of the subject of interest, the main objective of this project is to study the influence of a physical exercise program in patients undergoing catheter ablation of AF on different morphological and physiological variables of the heart, levels of physical activity and quality of life of patients. Investigators intend to recruit 120 participants, who will be randomly and equally distributed into a group that will perform a physical exercise intervention and a control group that will not perform any type of intervention. Participation in the study will not disrupt the normal practice of the health care system with these patients.

Read the detailed description

This is a randomized, controlled trial. The study will be conducted in collaboration with researchers from the GENUD (Growth Exercise NUtrition and Development) and BSICoS (Biomedical Signal Interpretation and Computational Simulation) research groups at the University of Zaragoza (Spain), and also with the Hospital Clínico Universitario Lozano Blesa, Zaragoza (Spain), specifically with the arrhythmia department of the cardiology service of that hospital.

The main objective of the study is to study the effect of physical exercise in people who have undergone atrial ablation at least one year ago on AF recurrence, heart morphology and function, level of physical activity, sleep quality, physical condition, quality of life, and hospitalization or adverse events. In addition, investigators also aim to assess gender differences in response to physical exercise after atrial ablation on the above-mentioned variables. Due to the characteristics of the project, insurance has been contracted to cover possible risks that may be contemplated during training and evaluations.

The first phase of the study corresponds to the recruitment of subjects and will be carried out among patients in the Arrhythmia Unit of the Hospital. All patients who have been undergoing catheter ablation as a medical treatment for AF for one year will be invited to participate and all those who wish to participate in the study must complete the informed consent form. Therefore, the incorporation of participants in the study will be periodic (weekly and/or monthly) and "drop-by-drop".

The subjects who will participate in the study will be patients, women and men, over 18 years of age, who underwent catheter ablation as medical treatment for AF and who currently have no recurrence of this arrhythmia. The inclusion and exclusion criteria are detailed in the corresponding section.

To calculate the sample size, a statistical power analysis was performed through the G*Power program with the following input parameters to obtain the effect of time: effect size (f = 0.25), type I error (α = 0.05), power level or type II error (0.95), number of measurements (3: pre-, post-ablation and follow-up). Our analysis revealed a total sample size of 54 individuals per group. Based on the previous years' care activity, the investigators expect to recruit at least 60 patients for each group (intervention and control) to guarantee the number of 54, considering a dropout around 10%.

All participants (both groups) will be evaluated at 3 points in time. The first evaluation will be at the time of recruitment, prior to the start of the physical exercise intervention (month 0), to determine the patient's initial condition. The second evaluation will take place after the end of the intervention (month 3), to study the effects of physical exercise and the last one 6 months after recruitment, to assess the detraining of the intervention group and continue with the follow-up of the control group.

All assessments will consist of two days of measurements. One day will include physical fitness, physical activity, body composition and quality of life questionnaires and the other day will include cardiac assessment by echocardiogram and electrocardiogram. Each of the measurements is mentioned below (the measures are described in the corresponding section):

  • Body composition.
  • Electrocardiogram (ECG).
  • Echocardiogram.
  • Objective physical activity.
  • Sleep analysis.
  • Muscle strength.
  • Cardiorespiratory capacity.
  • Quality of life.
  • Assessment of atrial fibrillation load.

The experimental design of the project is a randomized controlled trial where subjects will be assigned to one of two groups randomly defined using the randomizer.org website, considering sex and age: (a) control group, which will receive usual medical care and (b) experimental group, which will carry out a training program described below.

The intervention group will carry out a concurrent training program for 12 weeks, designed based on the scientific evidence currently available and following the latest recommendations (year 2023) for the diagnosis and management of AF from the American College of Cardiology (ACC) and the American Heart Association (AHA). During the 12 weeks of training (3 months) the weekly frequency will be 3 days per week. The duration of the sessions will increase progressively from week 1 to week 4. The sessions consist of resistance and aerobic training, and are divided into warm-up, resistance training with free weights (8 exercises, 3 for the lower body and 5 for the upper body), aerobic training on a cycle ergometer and a cool-down with stretching. Aerobic training will increase in duration from week 1 (30 min/day) to week 5 (50 min/day), following the principle of training progression. The same will be done with resistance work, being carried out once a week during the first 4 weeks and twice a week from weeks 5 to 12, adjusting the workloads individually based on the patient's progression.

The intensity of the training will be moderate and always individualized, based on the theoretical maximum heart rate (HRmax) calculated with the equation of Gellish et al. [207-(0.7*age)] for aerobic work (64-74% FCmax) and in repetitions in reserve (RIR) for resistance work (4-6). Overall, the perceived sense of effort is intended to be around 3-4 on the modified Borg scale (0-10). To perform a subsequent analysis of adherence to the physical exercise program by these patients, an individual attendance record will be made at the training sessions.

Being tested
Exercise
Medical subject headings
Atrial Fibrillation, Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ExerciseOther

    Also called Concurrent training, Physical exercise

    12 weeks of concurrent training, which is understood as a combination of strength and aerobic exercises, not necessarily in the same training session. The weekly frequency will be 3 times per week. The aerobic component of the session will last between 30 and 50 minutes (increasing as the weeks go by) and the strength work will be made up of 8 exercises (3 upper body and 5 lower body). The intensity of the training will be individualized and always moderate.

Study groups in NCT06832033
Study groupRoleWhat they receive
Control groupNo interventionNot described
Training groupActive comparatorThis group carried out a concurrent physical exercise intervention for 12 weeks
Receives: Other: Exercise

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Atrial fibrillation burden

    By subcutaneously implanting an insertable Holter device, the exact time in AF can be accurately quantified, since this type of device continuously monitors the heart rhythm throughout its battery life (3 years). This allows all subclinical and clinical AF episodes and their duration to be recorded.

    Measured: 6 months

  2. Echocardiogram

    It will be performed by a single observer with a Vivid iQ model echocardiograph following the latest recommendations.

    Measured: 6 months

  3. Cardiorespiratory capacity

    A 6-minute walking test will be performed to assess the subjects' cardiorespiratory capacity.

    Measured: 6 months

Secondary outcomes (10)
  1. Body composition

    Bioimpedance. A bioimpedance analyzer (TANITA MC-780) will be used to estimate fat mass.

    Measured: 6 months

  2. Body composition

    Bioimpedance. A bioimpedance analyzer (TANITA MC-780) will be used to estimate fat-free mass (muscle and bone mass).

    Measured: 6 months

  3. Electrocardiogram (ECG)

    Description and study of the ECG P wave, obtained from both single leads and combined information from multiple leads.

    Measured: 6 months

  4. Electrocardiogram (ECG)

    Study of heart rate variability (HRV) from the index of standard deviation of NN intervals (SDNNN).

    Measured: 6 months

  5. Electrocardiogram (ECG)

    Study of heart rate variability (HRV) from the root mean square of successive differences (RMSSD).

    Measured: 6 months

  6. Objective physical activity

    An Axivity X6 triaxial accelerometer (Newcastle upon Tyne, UK) will be used, which will be worn by the subject on the non-dominant hand for two weeks 24h a day. The recording frequency will be at 100Hz. The files will be analyzed through R-4.3.2 version of R software (http://cran.r-project. org), making use of the GGIR 3.0.5 package. The following variables will be generated and computed for all valid days: average acceleration (mg); total time in physical activity of moderate or vigorous intensity classified according to the cut-off point of 100 mg; the intensity gradient; the acceleration or intensity above which the X most active minutes are accumulated in the day (Mx, mg): M480, M120, M60, M30, M15, M10, M5, M2.

    Measured: 6 months

  7. Sleep analysis

    The R work package GGIR also allows for extracting sleep analysis information from data collected with accelerometers. Time periods with low variability in the accelerometer z-angle (i.e. <5° in 5 minutes) will be used and are defined as periods of sustained inactivity. Periods of sustained inactivity within these hours will be classified as sleep time. Data will be obtained on: sleep onset and end times, periods of wakefulness after sleep onset, and sleep efficiency.

    Measured: 6 months

  8. Muscle strength

    A hand-held dynamometer (TAKEY TKK-5401) will be used to measure handgrip strength. Two maximum strength measurements will be taken for each limb, in a bipedal position and with the arm extended and separated from the body. To evaluate lower body strength, the sit-to-stand test of 5 repetitions will be performed and then the 30-second test.

    Measured: 6 months

  9. Quality of life questionnaire

    The 36-Item Short Form Survey (SF-36) is an outcome measure instrument that is often used, well-researched, self-reported measure of health. The SF-36 measures eight scales: physical functioning (PF), role physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE), and mental health (MH). The results/scores for the entire scale and for each item separately are between 0 and 100.

    Measured: 6 months

  10. Quality of life questionnaire

    EuroQol-5D (EQ-5D). The EQ-5D descriptive system is a preference-based HRQL measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The 5 dimensions are classified in a score from 1 to 3 and a last question where you rate your health from 0 to 100.

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Feb 2025
  2. Study start9 Sep 2024
  3. Primary completionDec 2025 (estimated)
  4. Study completionSep 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06832033
Sponsor's protocol ID
PI24/174
Status last verified
Jan 2025
First submitted
29 Jan 2025
Last updated
18 Feb 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Exercise in people with Atrial Fibrillation (AF) and Physical Exercise, run by Marcos Echevarría at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 18 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Marcos Echevarría Polo, PhD Student (+34 640554122, mechevarria@unizar.es), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Atrial fibrillation burden (time frame: 6 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in